At the news
? NEUTRALIMPACT 3/10 PTAB-TRIAL filed Nov 9, 2026 at 19:00 ET
The PTAB granted institution of a post-grant review (PGR2026-00060) on Neurocrine Biosciences' challenge to Spruce Biosciences' U.S. Patent 12,569,490 covering methods for treating testicular and ovarian adrenal rest tumors. The decision is interlocutory, no claims have been cancelled, and the trial will proceed on the merits.
- PTAB granted institution of PGR2026-00060 on November 10, 2026
- Patent U.S. 12,569,490 covers methods for treating testicular and ovarian adrenal rest tumors
- Neurocrine Biosciences is the petitioner; Spruce Biosciences is the patent owner
- The decision is interlocutory, no claims have been cancelled or held unpatentable
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access